The Evolution of Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension

Tannu, Manasi; Krasuski, Richard A.

doi:10.1016/j.iccl.2023.03.005

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 , 20 , 21 , 22 , 23 , 24 , 25 These findings have been comprehensively reviewed. 26 , 27 However, the precise mechanisms underlying the effects of PADN remain a topic of ongoing debate. In a study by Zhou et al ., 28 a canine model of PAH was established using dehydrogenized monocrotaline (DHMC), and the results indicated that PADN had the capacity to partially alleviate pulmonary vascular remodelling.…”

Section: Non‐pharmacological Neuromodulation Therapymentioning

confidence: 99%

Autonomic nervous modulation: early treatment for pulmonary artery hypertension

Xueyuan,

Yanping,

Jiaoqiong

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

Pulmonary artery hypertension (PAH) is a chronic vascular disease defined by the elevation of pulmonary vascular resistance and mean pulmonary artery pressure, which arises due to pulmonary vascular remodelling. Prior research has already established a link between the autonomic nervous system (ANS) and PAH. Therefore, the rebalancing of the ANS offers a promising approach for the treatment of PAH. The process of rebalancing involves two key aspects: inhibiting an overactive sympathetic nervous system and fortifying the impaired parasympathetic nervous system through pharmacological or interventional procedures. However, the understanding of the precise mechanisms involved in neuromodulation, whether achieved through medication or intervention, remains insufficient. This limited understanding hinders our ability to determine the appropriate timing and scope of such treatment. This review aims to integrate the findings from clinical and mechanistic studies on ANS rebalancing as a treatment approach for PAH, with the ultimate goal of identifying a path to enhance the safety and efficacy of neuromodulation therapy and improve the prognosis of PAH.

show abstract